Trial | NCT04203433  Report issue

Title

A Study of DLX105-DMP in Subjects With Plaque Psoriasis
A Pilot, Open-Label Study in Subjects With Mild-to-Moderate Plaque Psoriasis to Investigate the Dosing Feasibility, Safety, Tolerability, and Preliminary Efficacy of a Four-Week Multi-dose Regimen of DLX105-DMP Administered to a Target Lesion

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    10
A Pilot, Open-Label Study in Subjects with Mild-to-Moderate Plaque Psoriasis to Investigate the Safety, Tolerability, and Preliminary Efficacy of a Four-Week Multidose Regimen of DLX105-DMP Administered to a Target Lesion
Study Started
Mar 21
2022
Primary Completion
Sep 01
2022
Study Completion
Sep 01
2022
Last Update
May 03
2023

Drug DLX105-DMP

1mg applied to target lesion

DLX105-DMP Multi-Dose Twice Weekly Experimental

4 Weeks of 1mg DLX105-DMP applied to a target lesion twice weekly

DLX105-DMP Multi-Dose Once Weekly Experimental

4 Weeks of 1mg DLX105-DMP applied to a target lesion once weekly

Criteria 

Key Inclusion Criteria:

Signed and dated informed consent.
Subjects aged 18-75 years.
Male subject, or if female, must be surgically sterile, post-menopausal, or using acceptable birth control.
Stable chronic mild-to-moderate plaque psoriasis.

Key Exclusion Criteria:

Non-plaque-type psoriasis only (e.g., pustular, erythrodermic and guttate psoriasis, palmar, or plantar) at Screening.
Drug-induced psoriasis (i.e., new onset or exacerbation from beta-blockers, calcium channel inhibitors or lithium) within 3 months prior to Day 1.
Ongoing use of psoriasis treatments or inadequate duration of washout prior to Day 1
No Results Posted